Business
Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic
AUSTIN, Texas, April 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it is donating personal
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, April 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s Scripps Health for distribution to its front-line doctors, nurses and other health-care practitioners caring for patients affected by the COVID-19 pandemic.\n The Company said that it has tapped its own medical supplies to deliver 250 surgical face masks directly to Scripps Health, which has an immediate and critical need for the protective gear for its health care professionals. Scripps Health is a private, nonprofit integrated health care system in San Diego. Plus Therapeutics has had a longtime presence in San Diego. “As a company dedicated to health care, we recognize the need to assist the Scripps Health medical community, which is going above and beyond the call of duty right now,” said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. “The COVID-19 pandemic has few precedents in modern times, but we understand that defeating this virus requires the support of medical professionals and first responders at leading institutions like Scripps Health.” About Plus Therapeutics, Inc. Plus Therapeutics is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas. The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT. We have two lead drug product candidates in our pipeline, RNL™ and DocePLUS™, being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals. This diverse and experienced team is using our proprietary and versatile nanotechnology platform to reformulate and deliver approved chemotherapeutics and widely-used radiotherapeutics to provide meaningful benefits to patients and healthcare providers. The platform also serves as the foundation and affords us the oppor...